JAMA Network
About The Study: In this study including 4,819 women with benign breast disease (BBD) in the percutaneous biopsy era, overall risk of breast cancer was increased versus the general population (ductal carcinoma in situ and invasive cancer combined), similar to that in historical BBD cohorts. Development and validation of pathologic classifications including both BBD severity and multiplicity may enable improved breast cancer risk stratification.
Authors: Amy C. Degnim, M.D., of the Mayo Clinic in Rochester, Minnesota, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamasurg.2023.6382)
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
